The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing ...

Bristol Myers Squibb BMY announced that it has obtained FDA approval for the label expansion of Opdivo (nivolumab) plus Yervoy (ipilimumab). The regulatory body approved Opdivo plus Yervoy as a ...

Frontotemporal lobar degeneration (FTLD) is a neurodegenerative disease affecting the frontal and temporal lobes that ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

But "cancer drugs offering low or no added benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022 and cost more per beneficiary than high-added-benefit drugs, suggesting ...

Giardiasis, caused by the protozoan Giardia intestinalis, is the leading cause of intestinal parasitic infections in humans ...

Artificial intelligence (AI) has taken the biotech industry by storm, allowing companies to speed up the drug discovery process while also making it more cost-effective. With so many companies in the ...

Its marketed products include EYLEA, Dupixent, Libtayo, Kevzara ... Eylea is a VEGF drug that is injected into patients’ eyes and stops macular degeneration (the main cause of blindness in ...

If the FDA cleared Libtayo by its deadline of 28 February, the drug will join the clutch of checkpoint inhibitors vying for a slice of the first-line NLSCLC market, nipping at the heels of Merck ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab ... patients whose tumours have high PD-L1 expression brings the drug into competition with Merck & Co’s Keytruda (pembrolizumab), which ...

All communications regarding the USAN-adopted and INN-recommended rhenium Re 186 obisbemeda generic name will now utilize the proprietary name REYOBIQ™. "Branding is an important part of ...